Your browser doesn't support javascript.
loading
Cytokines and Hepatocellular Carcinoma: Biomarkers of a Deadly Embrace.
Pocino, Krizia; Stefanile, Annunziata; Basile, Valerio; Napodano, Cecilia; D'Ambrosio, Francesca; Di Santo, Riccardo; Callà, Cinzia Anna Maria; Gulli, Francesca; Saporito, Raffaele; Ciasca, Gabriele; Equitani, Francesco; Basile, Umberto; Marino, Mariapaola.
Affiliation
  • Pocino K; Unità Operativa Complessa Patologia Clinica, Ospedale Generale di Zona San Pietro Fatebenefratelli, 00189 Rome, Italy.
  • Stefanile A; Unità Operativa Complessa Patologia Clinica, Ospedale Generale di Zona San Pietro Fatebenefratelli, 00189 Rome, Italy.
  • Basile V; Clinical Pathology Unit and Cancer Biobank, Department of Research and Advanced Technologies, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
  • Napodano C; Synlab Data Medica, 35133 Padova, Italy.
  • D'Ambrosio F; Dipartimento di Scienze di Laboratorio e Infettivologiche, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Di Santo R; Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.
  • Callà CAM; Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.
  • Gulli F; Dipartimento di Neuroscienze, Sezione di Fisica, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.
  • Saporito R; Dipartimento di Scienze di Laboratorio e Infettivologiche, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Ciasca G; Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.
  • Equitani F; Clinical Biochemistry Laboratory, IRCCS "Bambino Gesù" Children's Hospital, 00165 Rome, Italy.
  • Basile U; Unità Operativa Complessa Patologia Clinica, Ospedale Generale di Zona San Pietro Fatebenefratelli, 00189 Rome, Italy.
  • Marino M; Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.
J Pers Med ; 13(1)2022 Dec 20.
Article in En | MEDLINE | ID: mdl-36675666
ABSTRACT
Hepatocellular carcinoma (HCC) represents a worldwide health matter with a major care burden, high prevalence, and poor prognosis. Its pathogenesis mainly varies depending on the underlying etiological factors, although it develops from liver cirrhosis in the majority of cases. This review summarizes the role of the most interesting soluble factors as biomarkers for early diagnosis and as recommended targets for treatment in accordance with the new challenges in precision medicine. In the premalignant environment, inflammatory cells release a wide range of cytokines, chemokines, growth factors, prostaglandins, and proangiogenic factors, making the liver environment more suitable for hepatocyte tumor progression that starts from acquired genetic mutations. A complex interaction of pro-inflammatory (IL-6, TNF-α) and anti-inflammatory cytokines (TGF-α and -ß), pro-angiogenic molecules (including the Angiopoietins, HGF, PECAM-1, HIF-1α, VEGF), different transcription factors (NF-kB, STAT-3), and their signaling pathways are involved in the development of HCC. Since cytokines are expressed and released during the different stages of HCC progression, their measurement, by different available methods, can provide in-depth information on the identification and management of HCC.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies / Screening_studies Language: En Journal: J Pers Med Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies / Screening_studies Language: En Journal: J Pers Med Year: 2022 Document type: Article Affiliation country:
...